Proteasome inhibitor combined with chemotherapy
This page covers all Proteasome inhibitor combined with chemotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 26S proteasome.
Targets
Phase 3 pipeline (1)
- CDD Plus Bortezomib · Beijing Chao Yang Hospital · Oncology
CDD Plus Bortezomib combines a chemotherapy regimen (CDD) with bortezomib, a proteasome inhibitor that blocks protein degradation to trigger cancer cell death.
Patent intelligence
- proteasome inhibitor combined with chemotherapy patent landscape — aggregated cliff calendar, attackable patents, originator estates